Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2014

View Archived Issues

Kolltan Pharmaceuticals acquires Xetrios Therapeutics

Liquidia forms oral health company Lq3 Pharmaceuticals

Asterias Biotherapeutics partners with Cancer Research UK on AST-VAC2 study

Genocea's universal pneumococcal vaccine enters phase II development

First-in-human results for MOR-103 in patients with MS

Meiji Seika Pharma presents preclinical data on OP-0595

SolaranRx and STC.UNM sign option agreement for melanoma-targeting technology

Nymox reports 8-month trial data for NX-1207

Lilly reports phase III RAISE trial meets primary endpoint of overall survival

Fragment-based drug discovery at Takeda identifies selective LMW BTK inhibitors

G1 Therapeutics' CDK inhibitor G1T28-1 enters phase I

Ultragenyx presents promising interim phase I/II results for rhGUS enzyme replacement therapy

Almirall presents novel inhaled compounds with the ability to reduce airway inflammation

A novel p62-ZZ domain blocker in animal models of multiple myeloma-associated bone disease

Eisai patents FGFR inhibitors

Ono Pharmaceutical identifies Trk-A inhibitors

Astellas Pharma and Kyoto University present anti-human CD3 epsilon MAb

FDA approves Rixubis for children with hemophilia B

FDA accepts filing of supplemental NDA for Vyvanse

Avanir reports phase II results for AVP-923 for agitation in Alzheimer's disease

Preclinical data on vesicular stomatitis virus-based Ebola vaccine published

Prosonix creates drug-only fixed-dose combinations for inhalation

Roche begins phase III trials of lampalizumab for geographic atrophy

FDA grants orphan drug designation to Lynovex for cystic fibrosis

AstraZeneca and Lilly to jointly develop and commercialize BACE inhibitor

FDA grants tentative approval to Salix's budesonide rectal foam for distal ulcerative colitis

VolitionRx reports topline results from colorectal screening study with NuQ test